Intranasal COVID-19 Vaccine Candidate Launches Phase 1 Study

Gaithersburg-based Altimmune, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID, a novel, single-dose, intranasal COVID-19 vaccine candidate.

Altimmune expects to commence patient enrollment in the Phase 1 clinical trial in the coming week.

“We believe the deployment of intranasal vaccines like AdCOVID will be essential to a successful global response to the pandemic,” said Vipin K. Garg, President, and CEO of Altimmune, in a press release. 

“FDA clearance of the IND marks an important step in developing a safe and effective vaccine designed to stimulate mucosal as well as systemic immunity following intranasal administration. Developing vaccines that can effectively prevent transmission is a growing imperative to block the spread of disease and combat the emergence of new variants. We look forward to the data from this trial in the coming weeks.”